Immuneering
IMRX
39 hedge funds and large institutions have $12.9M invested in Immuneering in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 7 closing their positions.
89% more capital invested
Capital invested by funds: $6.84M → $12.9M (+$6.07M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
11% more funds holding
Funds holding: 35 → 39 (+4)
1.89% less ownership
Funds ownership: 12.53% → 10.64% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$379K |
| 2 |
BlackRock
New York
|
+$182K |
| 3 |
Corient Private Wealth
Miami,
Florida
|
+$109K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$89.1K |
| 5 |
Millennium Management
New York
|
+$67.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1M |
| 2 |
Morgan Stanley
New York
|
-$456K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$401K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$126K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$108K |
IMRX Hedge Fund Activity: Q2 2025 in Review
39 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q2 2025, worth a combined $12.9M — up 89% from $6.84M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IMRX positions and 7 closed out — a net gain of 4 holders — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $379K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $1M sold.
- 39 institutional investors held Immuneering (IMRX) as of Q2 2025, up from 35 in Q1 2025.
- Funds reported $12.9M of Immuneering stock for Q2 2025, up 89% quarter-over-quarter.
- 11 funds opened new Immuneering positions in Q2 2025 and 7 closed out, a net change of +4 holders.
- The largest Immuneering buyer in Q2 2025 was Fidelity Investments, an estimated $379K added.
- The largest Immuneering seller in Q2 2025 was T. Rowe Price Associates, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2025.